Alphagan 2 mg/ml colirio en solución

DRUG2 trials

Sponsors

AbbVie Deutschland GmbH & Co. KG

Conditions

Recurrent Ovarian Cancer with High Folate Receptor-Alpha ExpressionRecurrent endometrial cancerand primary peritoneal cancer (EOC)fallopian tuberecurrent cervical cancerrecurrent epithelial ovarian

Phase 1

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Gynaecological Cancers

Active, not recruitingCTIS2023-506842-22-00

AbbVie Deutschland GmbH & Co. KGand primary peritoneal cancer (EOC), fallopian tube, recurrent cervical cancer +2

Start: 2025-05-19Target: 169Updated: 2025-12-22

Phase 2

A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

Active, not recruitingCTIS2023-505617-24-00

AbbVie Deutschland GmbH & Co. KGRecurrent Ovarian Cancer with High Folate Receptor-Alpha Expression

Start: 2024-11-05Target: 46Updated: 2025-12-15